



# A Novel Point-of-Care Test for Tuberculosis Diagnosis

Joint development with The Foundation for Innovative New Diagnostics (FIND\*), supported by the Global Health Initiative Technology (GHIT) Fund\*\*.



- Urine test
- Easy to use
- No power supply required
- Highly sensitive
- For people living with HIV
- CE mark certified, aim to obtain WHO recommendation in 2020

## Positioning of TB Diagnostic Tools in LMIC



Call1 “A Rapid Biomarker Based Non-Sputum based Test Detecting TB”  
High-Priority Target Product Profiles for New Tuberculosis Diagnostics (TPP) published by WHO, 2014

A study published in the Lancet Infectious Diseases found that FUJIFILM Test has higher diagnostic accuracy than the commercially available TB-LAM test.

	FUJIFILM Test	Alere Determine TB LAM Ag
Clinical sensitivity in HIV+	70.4% <sup>1</sup>	42.3% <sup>1</sup>
Clinical specificity in HIV+	95.7% <sup>1</sup>	98.2% <sup>1</sup>

1: Broger et al. Lancet Infect Dis 2019; [https://doi.org/10.1016/S1473-3099\(19\)30001-5](https://doi.org/10.1016/S1473-3099(19)30001-5)

\* FIND is a Geneva-based global non-profit organization dedicated to accelerate and promote the development and usage of new technologies that can meet diagnostic needs in developing countries for conditions including tuberculosis, malaria and AIDS.

\*\* The Global Health Initiative Technology (GHIT) Fund was established jointly by the Japanese government, Japanese pharmaceutical companies, the Bill and Melinda Gates Foundation, and the United Nations Development Program. A joint government-private sector partnership, the fund aims to produce innovative pharmaceutical treatments, vaccines and diagnostics in Japan in order to reduce rates of infectious diseases in the developing world.